ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression

Lavudi Kousalya; Banerjee Ananya; Li Na; Yang Yajing; Cai Shurui; Bai Xuetao; Zhang Xiaoli; Li Aidan; Wani Elsa; Yang Shyh-Ming; Zhang Junran; Rai Ganesha; Backes Floor; Patnaik Srinivas; Guo Peixuan; Wang Qi-EnUnited States
npj Precision Oncology2023DOI: 10.1038/s41698-023-00411-x
7阅读
引用收藏
分享

摘要

Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) have been approved for both frontline and recurrent setting in ovarian cancer with homologous recombination (HR) repair deficiency. However, more than 40% of BRCA1/2-mutated ovarian cancer lack the initial response to PARPi treatment, and the majority of those that initially respond eventually develop resistance. Our previous study has demonstrated that increased expression of aldehyde dehydrogenase 1A1 (ALDH1A1) contributes to PARPi resistance in BRCA2-mutated ovarian cancer cells by enhancing microhomology-mediated end joining (MMEJ) but the mechanism remains unknown. Here, we find that ALDH1A1 enhances the expression of DNA polymerase θ (Polθ, encoded by the POLQ gene) in ovarian cancer cells. Furthermore, we demonstrate that the retinoic acid (RA) pathway is involved in the transcription activation of the POLQ gene. The RA receptor (RAR) can bind to the retinoic acid response element (RARE) located in the promoter of the POLQ gene, promoting transcription activation-related histone modification in the presence of RA. Given that ALDH1A1 catalyzes the biosynthesis of RA, we conclude that ALDH1A1 promotes POLQ expression via the activation of the RA signaling pathway. Finally, using a clinically-relevant patient-derived organoid (PDO) model, we find that ALDH1A1 inhibition by the pharmacological inhibitor NCT-505 in combination with the PARP inhibitor olaparib synergistically reduce the cell viability of PDOs carrying BRCA1/2 mutation and positive ALDH1A1 expression. In summary, our study elucidates a new mechanism contributing to PARPi resistance in HR-deficient ovarian cancer and shows the therapeutic potential of combining PARPi and ALDH1A1 inhibition in treating these patients.

相关
加载中…
  • Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy
    Huddle, Brandt C.; Grimley, Edward; Chtcherbinine, Mikhail; Buchman, Cameron D.; Takahashi, Cyrus; Debnath, Bikash; McGonigal, Stacy C.; Mao, Shuai; Li, Siwei; Felton, Jeremy; Pan, Shu; Wen, Bo; Sun, Duxin; Neamati, Nouri; Buckanovich, Ronald J.; Hurley, Thomas D.; Larsen, Scott D.*European Journal of Medicinal Chemistry, 2021, 211: 113060.被引 10
  • Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer
    Gogola, Ewa; Rottenberg, Sven*; Jonkers, JosANNUAL REVIEWS,4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA, 2019.被引 41
  • Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade
    Chen, Tingting; Yu, Tong; Zhuang, Shuping; Geng, Yiding; Xue, Junwen; Wang, Jiayi; Ai, Liqiang; Chen, Bo; Zhao, Zhangxiang; Li, Yawei; Wang, Jinghao; Liang, Haihai; Xu, Yan*; Gu, Yunyan*British Journal of Cancer, 2022, 127(5): 916-926.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
npj Precision Oncology
发表日期
2023
卷期
第 7 卷, 第 1 期
页码
66
DOI
10.1038/s41698-023-00411-x
成果收录
SCOPUS
资助标注
Cancer Research Center of Toulouse, France; Dr. Adam Karpf; Eppley Institute; OSUCCC; OSUCCC Pelotonia; Ohio State University Comprehensive Cancer Center; University of Nebraska; National Institutes of Health, NIH, (P30CA016058, R01CA211175, R01CA248027); U.S. Department of Defense, DOD, (W81XWH211028); National Cancer Institute, NCI

作者

  • L

    Lavudi Kousalya (第一作者)

    the ohio state university · united states

  • B

    Banerjee Ananya

    the ohio state university · united states

查看全部 16 位作者收起作者
  • L

    Li Na

    the ohio state university · united states

  • Y

    Yang Yajing

    the ohio state university · united states

  • C

    Cai Shurui

    the ohio state university · united states

  • B

    Bai Xuetao

    the ohio state university · united states

  • Z

    Zhang Xiaoli

    the ohio state university · united states

  • L

    Li Aidan

    united states · washington university in st. louis

  • W

    Wani Elsa

    the ohio state university · united states

  • Y

    Yang Shyh-Ming

    national institutes of health · united states

  • Z

    Zhang Junran

    the ohio state university · united states

  • R

    Rai Ganesha

    national institutes of health · united states

  • B

    Backes Floor

    the ohio state university · united states

  • P

    Patnaik Srinivas

  • G

    Guo Peixuan

    the ohio state university · united states

  • W

    Wang Qi-En

    the ohio state university · united states

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417